Phase 2 N=48 ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Pancreatic Cancer
Primary: Recurrence Free Survival — 15.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=79 A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
Type I Diabetes
Primary: Change From Baseline in HbA1c Levels — -0.12; 0.11 mmol/mol — p=0.0816
Phase 2 N=226 Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 — -58.4; -72.2; -73.4; -69.2 percentage change — p=0.051
N/A N=31,579 Electronic Health Record-Based Clinical Decision Support to Improve Blood Pressure Management in Adolescents
Hypertension · Pre Hypertension · Obesity
Primary: Participants With Clinical Recognition of Hypertension — 160; 51 Participants — p=<.001
N/A N=18 Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol
Type 1 Diabetes
Primary: Count of Participants Experiencing a Hypoglycemic Event During Scheduled Exercise — 3; 6 Participants — p=.45
Phase 4 N=110 Trigger Finger Corticosteroid Injection With and Without Local Anesthetic
Trigger Finger
Primary: Pain Outcome: Visual Analog Scale — 3.5; 2 score on a scale
Phase 2 N=60 Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 2 N=7 Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
Non-Small Cell Lung Cancer
Primary: The Number of Patients With Stage IIIB/IV NSCLC Response Rate to the Combination Therapy of Sorafenib and Docetaxel/Carboplatin
N/A N=484 Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)
Allogeneic Stem Cell Transplant · Graft Versus Host Disease · Hematologic Malignancy
Primary: Number of Participants With Acute Graft Versus Host Disease (GvHD) at Any Site (Grade II or Above) and Acute GvHD of the Gut of Any Grade — 75; 73; 31; 63 Participants
Phase 3 N=197 A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 42.9; 75.5; 83.7; 80.0 percentage of participants — p=<0.001
Phase 2 N=29 Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Surgical Exploration — 4; 6; 9 Participants
Phase 2 N=81 AZD1419 Ph2a Study
Asthma
Primary: Number of Participants With Events for Time to Loss of Asthma Control (LOAC) up to Week 52 - Cox Regression Analysis — 24; 24 Participants — p=0.5722
Phase 3 N=21 Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
Pediatric Ulcerative Colitis
Primary: Percent of Patients Who Achieved CAI Remission — 60.0; 80.0; 80.0; 77.8 percentage of participants
N/A N=27 ClariFix Cryoablation Clinical Study
Rhinitis
Primary: Device- and/or Procedure-related Serious Adverse Events — 0 participants
N/A N=46 Yoga to Prevent Mobility Limitations in Older Adults
Aging · Mobility Limitation · Sedentary Lifestyle
Primary: Short Physical Performance Battery (SPPB) — 1.55; 1.18 units on a scale